中外健康文摘
中外健康文摘
중외건강문적
WORLD HEALTH DIGEST
2012年
51期
99-101,102
,共4页
FAS -670%基因多态%非小细胞肺癌%吉非替尼
FAS -670%基因多態%非小細胞肺癌%吉非替尼
FAS -670%기인다태%비소세포폐암%길비체니
FAS -670%polymorphism%non-small-cell lung cancer%gefitinib
目的研究FAS -670A/G基因多态与吉非替尼治疗敏感性及患者生存之间的关系.方法入组88例接受吉非替尼单药治疗的I IA-IV期非小细胞肺癌患者,分析FAS -670A/G基因多态与吉非替尼治疗的临床获益率及患者生存的相关性.结果 FAS -670A/G基因多态与全组患者临床获益率无关.AA、AG、GG患者的2年总生存率分别为49.2%、49.2%和28.7%,有显著差异(P=0.028);携带A等位基因的患者,2年总生存率高于GG基因型患者,分别为49.3%和28.7%,有统计学意义(P=0.007).多因素预后分析显示病理类型(P=0.020,RR:2.466,95%CI:1.150-5.288)和FAS -670多态性(P=0.036,RR:0.503,95%CI:0.264-0.955)是独立的预后因素.结论促进肿瘤细胞凋亡是吉非替尼抗肿瘤作用的重要部分,FAS -670A/G基因多态可能成为吉非替尼治疗的进展期非小细胞肺癌患者生存的预测指标.
目的研究FAS -670A/G基因多態與吉非替尼治療敏感性及患者生存之間的關繫.方法入組88例接受吉非替尼單藥治療的I IA-IV期非小細胞肺癌患者,分析FAS -670A/G基因多態與吉非替尼治療的臨床穫益率及患者生存的相關性.結果 FAS -670A/G基因多態與全組患者臨床穫益率無關.AA、AG、GG患者的2年總生存率分彆為49.2%、49.2%和28.7%,有顯著差異(P=0.028);攜帶A等位基因的患者,2年總生存率高于GG基因型患者,分彆為49.3%和28.7%,有統計學意義(P=0.007).多因素預後分析顯示病理類型(P=0.020,RR:2.466,95%CI:1.150-5.288)和FAS -670多態性(P=0.036,RR:0.503,95%CI:0.264-0.955)是獨立的預後因素.結論促進腫瘤細胞凋亡是吉非替尼抗腫瘤作用的重要部分,FAS -670A/G基因多態可能成為吉非替尼治療的進展期非小細胞肺癌患者生存的預測指標.
목적연구FAS -670A/G기인다태여길비체니치료민감성급환자생존지간적관계.방법입조88례접수길비체니단약치료적I IA-IV기비소세포폐암환자,분석FAS -670A/G기인다태여길비체니치료적림상획익솔급환자생존적상관성.결과 FAS -670A/G기인다태여전조환자림상획익솔무관.AA、AG、GG환자적2년총생존솔분별위49.2%、49.2%화28.7%,유현저차이(P=0.028);휴대A등위기인적환자,2년총생존솔고우GG기인형환자,분별위49.3%화28.7%,유통계학의의(P=0.007).다인소예후분석현시병리류형(P=0.020,RR:2.466,95%CI:1.150-5.288)화FAS -670다태성(P=0.036,RR:0.503,95%CI:0.264-0.955)시독립적예후인소.결론촉진종류세포조망시길비체니항종류작용적중요부분,FAS -670A/G기인다태가능성위길비체니치료적진전기비소세포폐암환자생존적예측지표.
Objective To investigate the association between polymorphism in FAS -670A/G and the clinical benefit and outcome of advanced Non-Small-Cell Lung Cancer patients treated with gefitinib. Methods 88 patients with advanced NSCLC treated with gefitinib were enrolled. Polymerase chain reaction based restriction fragment length polymorphism assay was used to determine the genotypes. Results We found that FAS -670 AG+AA genotype carriers had a significantly longer overall survival time than GG genotype carriers (P=0.007 ). After the multi-variants’ cox regression analysis, pathological types (P=0.020,RR: 2.466, 95%CI: 1.150-5.288) and FAS -670 genotype (P=0.036,RR: 0.503, 95%CI: 0.264-0.955) were found to be independent prognostic factor for these patients. Conclusion FAS -670A/G could be predictor of survival for advanced NSCLC patients treated with gefitinib.